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Abstract 
JD27 is a derivatives of active ingredient extracted from Rabdosia which includes a functional group of 1,2,3-Triazoles. It is 
considered as a promising anti-cancer drug candidate because of its low toxicity and broad-spectrum anti-cancer activity. 
However, the clinical application of JD27 has been limited by its poor solubility. Albumin is an attractive macromolecular carrier, 
which has been widely used in nanoparticle preparation. Compared with other drug delivery systems, drug-loaded albumin 
nanoparticles showed a series of advantages such as solubilization of hydrophobic drug, biodegradable, biocompatible and so on. 
In this study, JD27-loaded human serum albumin nanoparticles (JD27-NPs) were obtained using an established desolvation 
method and they were characterized by particle size, zeta potential, encapsulation efficiency, surface morphology and in vitro 
drug release studies. In addition, their cytotoxic activities, intracellular kinetics and cell membranes permeability were evaluated 
in EC-9706 cells. The experiment results showed that the particle size, zeta potential, and encapsulation efficiency were 
(276.5±8.26) nm, (−41.4±7.21) mV and 82.2%±5.09%, respectively. SEM images suggest that JD27–NPs were a round shape, 
similar uniform size and smooth surface. Drug release studies indicated JD27-NPs had the properties of sustained release. The 
results of cytotoxic activities suggest that antitumor efficacy of JD27–NPs is higher than JD27 in EC-9706 cells. According to 
the results of intracellular kinetics, the concentration of JD27-NPs in the cell could reach the peak concentration after 2 hour and 
gradually decreases with time lasted. The AUC0-12h and MRT of JD27-NPs are significantly higher than that in JD27 (P<0.05). 
JD27-NPs have advantages to keep a higher and steadier intracellular concentration than JD27 which shows JD27-NPs have 
priority in application. The results of Hoechst 33258 staining suggested that the permeability of the cells membrane can be 
changed with the different concentration and treatment time of JD27. In conclusion, albumin nanopaticles may act as a useful and 
safe carrier for JD27.JD27-NPs will be a promising formulation for cancer therapy in future. 
© 2014 The Authors. Published by Elsevier Ltd. 
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Academy of Sciences (CAS). 
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1. Introduction 
1,2,3-Triazole which is a reactive group can be found in a wide range of bioactive molecules such as 
antimicrobial[1,2], anti-hypersensitivity[3], anti-tuberculosis [4,5],anti-inflammatory agents[6] and anti-HIV agents 
[7,8].In recent years, much attention has been paid to their anticancer activity, recent research report that1,2,3-
Triazoles exhibit effective anticancer activity [9-16]. JD27 which includes a functional group of 1,2,3-Triazoles is a 
derivatives of active ingredient extracted from Chinese traditional medicine Rabdosia rubescens. JD27 is considered 
as a promising anti-cancer drug candidate because of its low toxicity and broad-spectrum anti-cancer activity. 
However, JD27 shows a very low water solubility, which limits its clinical use. Large efforts are ongoing to develop 
drug carrier systems that improve drug solubility. 
Among the different formulation strategies used to deliver insoluble drugs, albumin-based nanoparticle is a very 
effective approach to improve drug solubility. Albumin, a multifunctional protein carrier for drug delivery, has 
drawn considerable attention in the pharmaceutical fields in view of non-toxic, non-immunogenic, good 
biocompatible and biodegradable [17-19].Albumin nanoparticles have gaining increasing interesting due to a higher 
capacity of loading hydrophilic drugs. Different from nanoparticles made of synthetic polymers, HSA nanoparticles 
are considered no significant side effects and well-tolerated in vivo [20-22], which is supported by the findings of 
several clinical studies on HSA-based particle products such as Albunex™[23,24] and Abraxane™[25,26]. 
Furthermore, it has a unique feature of entering tumor cells through the well-known gp60 pathway which can 
enhance the bioavailability and distribution of drug, reducing the body's response towards drug resistance and 
diminishing their toxicity [27, 28].Therefore, nanoparticles made of HSA will be a promising strategy for targeted 
delivery of anticancer drugs to tumor cells. 
Albumin nanoparticles can be prepared by several methods including desolvation [29, 30], emulsification [31, 
32], self-assembly [33, 34], nab-technology [35, 36] techniques. Among all the methods, desolvation process is a 
robust and reproducible method for the denaturation of albumin [37]. Zhao et al [29] successfully prepared 
nanoparticles of folate-conjugated water insoluble paclitaxel-loaded bovine serum albumin by a desolvation 
technique. The paclitaxel-loaded bovine serum albumin can significantly increased water solubility of paclitaxel. Li 
et al[30] produced oridonin loaded bovine serum albumin nanoparticle (ORI-BSA-NP) and oridonin loaded 
galactosylated bovine serum albumin  nanoparticle  (ORI-GB-NP) by the desolvation technique The results of 
characteristics and in vitro drug release of ORI-GB-NP show that the nanoparticles  possessed  fine  
physicochemical characteristics  and will be a stable delivery system for poorly soluble oridonin. 
The objective of study is to develop a novel nano-drug delivery system JD27-loaded human serum albumin 
nanoparticle (JD27-NPs). Firstly, JD27-NPs were obtained using an established desolvation method [38]. Then, the 
physicochemical characteristics including particle size, zeta potential, encapsulation efficiency and surface 
morphology and in vitro drug release studies were determined. In addition, cytotoxic activities and intracellular 
kinetics of these nanoparticles were also investigated. 
2. Materials and methods 
2.1. Chemicals and reagents 
Human serum albumin (HSA, purity 99%, 65,000Da) obtained from Sigma (Steinheim, Germany). JD27 was a 
gift of School of Pharmaceutical Sciences of Zhengzhou University School. Hoechst 33258 fluorescence apoptosis 
detection kit was purchased by Keygen Biotechnology Development Co., Ltd.. RPMI 1640 cell culture medium and 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide(MTT) were bought from Gibco Invitrogen. Ethanol 
and ethyl acetate were used as analytic reagents. Methanol and acetonitrile were of high performance liquid 
chromatography grade. An EC-9706 human esophageal cancer cell line was obtained from the Chinese Academy of 
Sciences Cell Bank. 
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2.2. Preparation of JD27-NPs 
JD27-NPs were prepared using an established desolvation method [38]: an amount of HSA was dissolved in 
distilled water and the pH was adjusted to 9 with 0.1 M NaOH. A certain amount of JD27 was dissolved in 10ml 
ethanol. The solution was continuously (1ml/min) added to albumin solution under permanent stirring (600 rpm) at 
room temperature. Following the desolvation process the particles were cross-linked by adding predetermined 
volume of 25% glutaraldehyde (10-40μl) and stirred at room temperature for 12h. In order to remove unreacted 
chemicals and free HSA molecules, the resulting nanoparticles were purified by three cycles of differential 
centrifugation (15,000rpm, 30 min) and finally redispersion in water. 
2.3. Measurement of particle size and zeta potential 
Size distribution and zeta potential of JD27-NPs were measured by dynamic light scattering DLS (Zetasizer Nano 
ZS-90, Malvern, UK). The samples were diluted 1:50 with purified water and were measured at a temperature of 
25°C.Every sample was measured for three times. 
2.4. Determination of encapsulation efficiency 
JD27-NPs were separated from the aqueous suspension medium by ultracentrifugation of 15,000rpm at 4°C for 
30min.The amount of free JD27 in the clear supernatant was determined by high performance liquid 
chromatography(HPLC, 1100 Agilent, USA).The HPLC system comprised of a pump and UV-Vis detector with a 
Diamonsil TM ODS C18 column(4.6mm×150mmˈ5μm) was used for the quantification of JD27 in the samples. The 
mobile phase was a mixed of water and acetonitrile (70:30) containing 0.1% phosphoric acid . The flow rate was set 
to 1ml/min with detection at 240nm. Aliquot of 20μl clear supernatant was injected into HPLC. The working curve 
was obtained by standard JD27 solutions with different concentrations over the range of 0.25-100.0 μg/ml. 
Encapsulation efficiency was calculated using the following equations: 
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2.5. Surface morphology 
The shape and surface morphology of JD27-NPs were investigated by scanning electron micrograph (SEM, JSM-
5610LV, JEOL Ltd., Tokyo, Japan). 
2.6. In vitro drug release studies 
0.5 ml JD27-NPs (2mg/ml) solution was dialyzed (cutoff Mw14 kDa) against 25ml release PBS buffer at 37°C in 
a water bath at 100rpm. Sample were taken at predetermined times outside of the release medium and the same 
volume of fresh buffer was added, and the concentrations of JD27 were determined by HPLC under the above 
chromatographic conditions. The release experiments were repeated three times and the cumulative percentage of 
drug release was reported. 
2.7. Cell culture 
The EC-9706 cells were cultured in RPMI1640 medium with 10% fetal calf serum (FCS) plus penicillin (100 
IU/ml) and streptomycin (100μg/ml). The EC-9706 cells were propagated in an incubator with a humidified 
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atmosphere of 5%CO2 in air at 37°C and seeded in new medium every 2-3 days, and were in the exponential phase 
of growth at the time of inclusion in assay. 
2.8. In vitro cytotoxicity 
MTT method is used to compare in vitro cytotoxicity between JD27-NPs and JD27 on EC-9706 cells. Briefly, 
EC-9706 (104 cells) were plated in each well of a 96-well plate and were allowed to adhere and spread for 24h. The 
cells were incubated with serial concentrations of JD27 and JD27-NPs (2-32μg/ml)at 37°C for 24h and 48h.MTT 
solution (20μl of 5mg/ml) was added to each well, and incubated for an additional 4h. After 4h, MTT-formazan 
crystals were dissolved in 150μl DMSO. The absorbance was measured on microplate reader (BIO-Rad, United 
States) at the wavelength 490nm and compared with control, untreated cells. For all experiments, results were 
obtained from triplicate experiments using SPSS software (version 17.0).  
At the same time , in order to directly perceived the effect of JD27-NPs on EC-9706, the EC-9706 were treated 
respectively with different concentrations of JD27-NPs (4μg/ml,16μg/ml,32μg/ml) for 48h, and the cell morphology 
was observed with inverted microscope. 
2.9. Hoechst 33258 staining 
EC-9706 cells were seeded at 2×105 cells/well in 6-well plates and incubated for 24h (Place a clean sterile blood 
cover sheet in each well of a 6-well plate so that tumor cells can be adhere on it). Then the medium was replaced 
with fresh medium containing different concentrations of JD27 (16μg/ml, 32μg/ml). After incubation for different 
durations(4h and 8h), the culture plates in cell culture medium was discarded, the cells were fixed for 10 min at 4°C 
using4% formaldehyde, then formaldehyde was discarded and the cells were washed gently with PBS twice. Finally, 
100μl Hoechst 33258 was added, and changes of the blue fluorescence in stained cells were observed by using an 
fluorescence microscopy (Nikon, Eclipse 80i). 
2.10. Intracellular kinetics studies 
2.10.1. HPLC condition 
Concentrations of JD27 in cell lysates were detected using HPLC systems. The samples were passed through a 
reverse-phase column ( Diamonsil TM ODS C18 column,4.6mm×150mm,5μm). The mobile phase was a mixed of 
water and acetonitrile (75:25) containing 0.1% phosphoric acid. The flow rate was set to 1ml/min with detection at 
240nm.  
2.10.2. Determination of intracellular JD27 
After incubation with JD27-NPs or JD27 the medium was removed, and cells were washed three times with cold 
phosphate buffer saline (PBS). Cells were harvested by trypsinization prior to counting. The intracellular 
concentrations of JD27 were determined as follows: the cells were ruptured by ultrasonic cell crusher (JY92-Ċ, 
Ningbo Chi Bio-Technology Co., Ltd.). A volume of 6.0 ml ethyl acetate was added to the simples as extractant. The 
mixture was vortex-mixed for 5min and centrifuged for 15min at 4500rpm.5.5ml of the organic supernatant was 
transferred to another tube and evaporated at 40°C to dryness under an N2 stream. The residue was reconstituted in 
100μl of mobile phase methanol and following vortex mixing for 5 min and centrifugation at 12000 rpm for 15min, 
20μl of supernatant was injected into the HPLC system. Concentrations of JD27 in cell lysates were calculated 
relative to a calibration curve. 
2.10.3. Intracellular kinetics studies 
EC-9706 cells were seeded in culture dish and incubated for 24h. The medium was then removed, and fresh 
medium containing same concentrations of JD27 and JD27-NPs (8μg/ml) was added. After incubation for different 
durations (0.5h, 1h, 2h, 4h, 8h,12h). The concentrations of intracellular were determined as described above. The 
results were obtained from triplicate experiments using Kinetica software (Version 4.4.1). 
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3. Results and discussion 
3.1. Characterization of nanoparticles 
JD27-NPs were characterized for size, zeta potential, encapsulation efficiency and Surface morphology. The size 
and zeta potential were (276.5±8.26) nm (Fig.1b) and (−41.4±7.21) mV (Fig.1c), respectively. In Fig 2ˈJD27-NPs 
were observed by SEM, which had a round shape, smooth surface and similar uniform size. The obtained JD27-NPs 
were well dispersed without aggregation (Fig.1a). 
 
Fig.1 Characterization of JD27-NPs (a) JD27-NPs; (b) Particle size of JD27-NPs;(c) zeta potential of JD27-NPs. 
 
 
Fig.2 Scanning electron micrograph (SEM) of JD27-NPs 
In desolvation process, single factor design including the concentration of HSA and JD27, the amount 
desolvating agent and cross-linker, cross-linking time and pH were investigated to optimize the formula and 
technology for preparing JD27-NPs. According to the single factor test, the amount of desolvating agent added and 
the pH of HSA solution were identified as the major factor determining the particle size. Varying these parameters, 
mean particle diameters could be adjusted to about 270nm, higher pH values leading to smaller nanoparticles. 
Taking the size, the zeta potential, especially the entrapment efficiency into account, we identified the best formula 
for preparing JD27-NPs. 
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Fig.3a illustrates the in vitro release of JD27solution and JD27-NPs.The accumulative release of JD27-NPs was 
about 15% at 0.5 h, and 60% at 48 h, respectively .Meanwhile, the accumulative release of JD27 solution was about 
40% at 0.5 h and 93% at 48 h, respectively. The release rate of JD27-NPs significantly slower than that in pure JD27 
solution, and it became slower with increasing time. The above data indicated that JD27-NPs were showing the 
sustained-release effect. The calibration curve of JD27 was y =9727.6x + 609.08 with a correlation coefficient of 
0.9999 in the concentration range of 0.25-100.0 μg/ml. (y: peak area; x: concentration of JD27, μg/ml) (Fig.3b). 
According to the calibration curve, the encapsulation efficiency was 82.2%±5.09%. 
 
 
Fig. 3 (a) Release profiles of JD27 from JD27-NPs and JD27 solution (mean ± SD, n=3); (b) Calibration curve of JD27. 
The study of drug release indicated JD27-NPs had sustained release effect which enabled JD27 release more 
stably and continuously. Sustained release effect of JD27-NPs provides the possibility to fight continually against 
cancer cells, resulting in decreased cancer cell viability. The generally sustained and controlled release profile of 
JD27-NPs facilitated the application of nanoparticles for the delivery of anticancer drugs. 
3.2. In vitro cytotoxicity  
The cytotoxicity studies of JD27-NPs and JD27 on EC-9706 cells were carried out with different concentrations 
of JD27-NPs and JD27. In this text, we designed the blank NPs group as the contrast to reduce its influences on 
results .As shown in Fig.4, cell inhibitions of blank NPs remained below 10% at all concentrations. These data 
indicates that the blank NPs had no obvious toxic effect on EC-9706 cells. According to the Fig.4, as the increasing 
of concentration and time of exposure of JD27-NPs and JD27, the effect against the EC-9706 cells gradually 
increased. Inhibition efficiency of JD27-NPs on EC-9706 cells was higher than JD27 (P < 0.05) at all the time 
point .In the table1,the IC50 of JD27 and JD27-NPs at 24h were 31.925μg/ml and 27.483μg/ml while the IC50 of 
JD27 and JD27-NPs were obtained at a concentration of 27.873μg/ml and 10.611μg/ml at 48h.Regarding the IC50 
values, JD27-NPs exhibited a higher inhibition efficiency on EC-9706 cells than JD27(P < 0.05) at 24h and 48h. 
Fig.5 illustrates the morphology of EC-9706 cells exposed to JD27-NPs by inverted microscope after 48h. We found 
that some cells is round and float , the contact of cells becomes loose, the proliferation was slowed down and the 
particle increased in cytoplasm with the increase of drug concentration and treatment time.  
 
Table1 IC50 Values of JD27 and JD27-NPs on EC-9706 cells (mean ± SD, n=3) 
Incubation  
Time(h) 
IC50(μg/ml) 
24h 48h 
JD27 31.925±1.35 27.873±0.73 
JD27-NPs 27.483±2.67 10.611±1.56 
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Fig .4 Inhibition of JD27 and JD27-NPs on EC-9706 cells at different time (a) 24h (mean ± SD, n=3); (b) 48h (mean ± SD, n=3) 
 
Fig.5 Morphology of EC-9706 cells exposed to JD27-NPs by inverted microscope after 48h (200×) (a)Control;( b)4μg/ml; (c)16.0 
μg/ml;(d)32μg/ml  
JD27-NPs significantly inhibits the growth of EC-9706 cell line by time-dependent and concentration-dependent 
in 24h and 48h, suggesting that the delivery system could efficiently cross cell membranes and afford higher 
antitumor efficacy on EC-9706 cells. JD27-NPs will be a promising formulation for cancer therapy in future. 
3.3. Hoechst 33258 staining 
Blue-fluorescent Hoechst 33258 may pass through the integral membrane of live cells. Condensed chromatin of 
apoptotic cells stained with Hoechst 33258 can emit more brightly blue-fluorescent than the looser chromatin of 
normal cells, which can monitor changes of nuclear associated with apoptosis. Therefore, the level of Hoechst 33258 
uptake indicates the permeability change of the cells membrane. 
Influence of JD27 on cell nuclear morphology of EC-9706 cells was presented in Fig.6 after 8h and 12h of 
incubation with different concentrations of JD27. Apoptotic cells staining with Hoechst 33258 can emit bright blue 
fluorescence. As shown in the Fig.6, percentage of apoptotic cells significant increased in a concentration-dependent 
and time-dependent manner, indicating that the level of Hoechst 33258 uptake increased. The enhanced uptake of 
Hoechst 33258 indicated that JD27 could change the permeability of cell membrane. With the increase of cell 
membrane permeability, the more JD27 could efficiently cross cell membranes resulting in a better anti-tumor effect.  
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Fig.6 Influence of JD27 on cell nuclear morphology of EC-9706 cells with Hoechst 33258 staining˄400×˅(a1and a2) control; ( b1)cells treated 
with 16μg/ml for 4h; (c1)cells treated with 16μg/ml for 8h; (b2) cells treated with 32μg/ml for 4h; (c2) cells treated with 32μg/ml for 8h. 
3.4. Intracellular kinetics studies 
The Intracellular kinetics curve of JD27 and JD27-NPs are shown in (Fig.7a). Uptake of JD27 and JD27-NPs 
increased as the time went on, reaching to the highest amount after 2h. As shown in the Table2 in comparison with 
JD27, AUC0-12h , MRT ,t1/2 Kel, t1/2 Ka of JD27-NPs were higher than JD27.The calibration curve of intracellular 
kinetics was y=0.008x-0.2178 with a correlation coefficient of 0.9967 in the concentration range of 25.0-800.0 
ng/ml. (y: peak area; x: concentration of JD27 in cell lysates , ng/ml) (Fig.7b). 
 
 
Fig. 7 (a)Intracellular kinetics of JD27andJD27-NPs in EC-9706 cells.EC-9706 cells were treated with 8μg/ml of JD27or JD27-NPs at 0.5,1,2,4,8 
and12h time points (mean ± SD, n=3); (b) Calibration curve of intracellular kinetics  
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Table 2 Kinetics parameters of JD27 and JD27-NPs after uptake by EC-9706 cells (mean ± SD, n=3) 
Formulation Parameters Unit Value 
JD27 kel 1/h 0.192429±0.02 
 t1/2 Ka h 0.170375±0.06 
 MRT h 4.41248±0.26 
 Cmax ng/106 cells 60.6693±0.31 
 Tmax h 1.57148±0.16 
 t1/2 Kel h 3.60209±0.23 
 AUC (ng/106 cells)·h 366.85±4.95 
JD27-NPs kel 1/h 0.2940859±0.08 
 t1/2 Ka h 0.191012±0.05 
 MRT h 9.84517±3.79 
 Cmax ng/106 cells  50.9572±10.22 
 Tmax h 1.41722±0.04 
 t1/2 Kel h 7.36717±2.46 
 AUC (ng/106 cells)·h 574.883±11.08 
 
The results of intracellular kinetics were consistent with previously obtained drug release curves in vitro, 
indicating that the JD27-NPs had a delayed-release effect. Compared with JD27, the JD27-NPs had obtained a much 
higher AUC0-12h (P<0.05), which indicating JD27-NPs can enhance the drug bioavailability on EC-9706 cells. 
Meanwhile, JD27-NPs also obtained a much longer MRT (P<0.05), which stood for prolonged drug duration on EC-
9706 cells. Intracellular parameters showed that JD27-NPs have advantages to keep a higher and steadier 
intracellular concentration than JD27, which shows JD27-NPs can promote JD27 intracellular uptake of EC-9706 
cells. It also indicates that JD27-NPs could make JD27 release more stably and continuously. JD27-NPs are likely to 
have a significant potential for in vivo anti-tumor efficacy in future. 
4. Discussion 
In the area of pharmaceutical research, nanoparticulate delivery systems are gradually became a hot spot research 
because nanocarriers have a series of advantages such as improve drug solubility, protect drugs from degradation, 
increase penetration and intracellular distribution . Nanoparticles based on albumin have received considerable 
interest due to high binding capacity of hydrophobic drugs and biocompatibility without any serious side effects. 
The smaller size (50-300 nm) and controlled release properties can improve patient compliance and acceptance. 
Moreover, human serum albumin (HSA) was selected as an ideal candidate for drug delivery due to its readily 
available, biodegradable and priority uptake. Thus, HSA is the ideal material to make nanoparticles for drug 
delivery [39-41]. Albumin-bound (NAB-) paclitaxel ABI-007(trade name Abraxane®; the company Abraxis 
BioScience and AstraZeneca), a novel , albumin-bound , 130-nm particle formulation of paclitaxel  is one of the 
sucessful strategies to solve solvent-related problems of paclitaxel[42]. Recently, the U.S. Food and Drug 
Administration have approved it for pretreated metastatic breast cancer patients. In this paper, we successfully 
prepared JD27-NPs with a particle size of about 270nm and high encapsulation efficiency. SEM images showed that 
JD27-NPs was a round shape, smooth surface and similar uniform size, which making the JD27-NPs have a higher 
penetration into tumor cells with an increased antitumor activity, compared with JD27. In addition, Human serum 
albumin substitute bovine serum albumin as nanocarriers to prepare the JD27-NPs could avoid a possible 
immunologic response in vivo. JD27-NPs show significant advantages to JD27 and will be a high potential 
formulation for the treatment of cancer. 
Gp60 is an endothelial cell membrane 60-kDa glycoprotein and has a high binding capacity to albumin. Albumin 
binding to a gp60 receptor seems to lead to combination of gp60 and an intracellular protein (caveolin-1) and 
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subsequently invagination of the cell membrane to form transcytotic vesicles. Thereby, the transcytosis of albumin 
across the endothelium of blood vessels is achieved through the well-known gp60 pathway which promoting the 
albumin-bound drugs into tumor cells [43-48].Furthermore, SPARC which is known as an extracellular matrix 
glycoprotein acid rich in cysteine is often seen in some neoplasms .It can bind to albumin, which further facilitates 
the intratumor accumulation of albumin-bound drugs [49-54]. In short, albumin will be actively and selectively 
recognized and bound by the two different proteins rich in the tumor tissues, which may explain the reason why 
albumin is known to accumulate in some tumors. Kim et al. prepared the CCM-loaded HSA-NPs by nab-technology 
and investigated the potential mechanisms about enhanced accumulation of curcumin (CCM) in tumor. They found 
that the endothelial transcytosis of CCM-HSA-NPs was completely suppressed by β-methyl cyclodextrin(known as 
a inhibitor of caveolar mediated transcytosis)[36].  
In this paper, according to the results of intracellular kinetics, compared with JD27, the JD27-NPs had obtained a 
much higher AUC0-12h (P<0.05) and a much longer MRT (P<0.05), which indicating JD27-NPs can enhance the 
drug bioavailability and prolong drug duration in EC-9706 cells. Therefore, JD27-NPs could improve JD27 
intracellular uptake of EC-9706 cells .The in situ data suggest that JD27-NPs uptake and antitumor activity was 
significantly increased by the use of nanoparticle delivery system. So we infer the possible mechanisms were to be 
due to increased transendothelial gp60-mediated transport and SPARC-albumin interaction [55-57]. In addition, the 
mechanisms of accumulation of JD27-NPs nanoparticles in EC-9706 remain to be identified next.  
5. Conclusion  
In summary, this study demonstrated that JD27, a water insoluble anticancer drug, could be successfully loading 
into albumin nanoparticles with a particle size of about 270nm and high encapsulation efficiency. In the view of the 
data of in vitro cytotoxicity obtained in this study, it can be concluded that albumin loading with JD27 had higher 
inhibition efficiency on EC-9706 cells than JD27. The intracellular kinetics was definitely proved that compared to 
JD27, JD27-NPs could enhance the drug bioavailability and prolong drug duration on EC-9706 cells. It is believed 
that JD27-NPs has priority in application and could be used to investigate the vivo effects of JD27.Our 
investigations suggest that albumin nanoparticles may act as a useful and safe carrier for JD27. JD27-NPs will be a 
promising formulation for cancer therapy in future. In addition, the vivo characters of JD27 remain to be identified. 
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